Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 460

1.

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.

Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Exp Med. 2018 Dec 6. doi: 10.1007/s10238-018-0541-2. [Epub ahead of print]

PMID:
30523507
2.

An uncommon histopathological diagnosis.

Bode H, Sciot R, Werbrouck E, Geusens E, Deroose CM, Nackaerts K.

Breathe (Sheff). 2018 Dec;14(4):311-316. doi: 10.1183/20734735.027418.

3.

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1.

PMID:
30274985
4.

Case Reports in Oncological Medicine Myoepithelioma: A New Rearrangement Involving the LPP Locus in a Case of Multiple Bone and Soft Tissue Lesions.

Pairet G, Tilman G, Sciot R, Schubert T, Perlepe V, Poirel HA, Galant C.

Case Rep Oncol Med. 2018 Feb 27;2018:3512847. doi: 10.1155/2018/3512847. eCollection 2018.

5.

A rare case of atypical/anaplastic meningioma with MDM2 amplification.

Wylleman R, Debiec-Rychter M, Sciot R.

Rare Tumors. 2018 May 31;10:2036361318779511. doi: 10.1177/2036361318779511. eCollection 2018.

6.

Orbital tumor associated with a microphthalmic eye and colobomatous cleft: Pilocytic astrocytoma (glioma) or massive retinal gliosis.

Van Ginderdeuren R, Sciot R, Mombaerts I.

Saudi J Ophthalmol. 2018 Jan-Mar;32(1):79-82. doi: 10.1016/j.sjopt.2018.02.011. Epub 2018 Mar 9.

7.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2019 Feb 1;30(2):344. doi: 10.1093/annonc/mdx823. No abstract available.

8.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.

Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15.

PMID:
29669701
9.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.

Eur J Cancer. 2018 May;94:156-167. doi: 10.1016/j.ejca.2018.02.011. Epub 2018 Mar 20.

PMID:
29567632
10.

Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center.

van Cann T, Cornillie J, Wozniak A, Debiec-Rychter M, Sciot R, Hompes D, Vergote I, Schöffski P.

Oncol Res Treat. 2018;41(4):206-213. doi: 10.1159/000486419. Epub 2018 Mar 23.

PMID:
29562223
11.

Evidence of amyloid-β cerebral amyloid angiopathy transmission through neurosurgery.

Jaunmuktane Z, Quaegebeur A, Taipa R, Viana-Baptista M, Barbosa R, Koriath C, Sciot R, Mead S, Brandner S.

Acta Neuropathol. 2018 May;135(5):671-679. doi: 10.1007/s00401-018-1822-2. Epub 2018 Feb 15.

12.

The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE.

Neuro Oncol. 2018 May 18;20(6):818-825. doi: 10.1093/neuonc/noy013.

PMID:
29409029
13.

Brain perfusion fixation in male pigs using a safer closed system.

Musigazi GU, De Vleeschauwer S, Sciot R, Verbeken E, Depreitere B.

Lab Anim. 2018 Aug;52(4):413-417. doi: 10.1177/0023677217752747. Epub 2018 Jan 10.

PMID:
29320926
14.

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthoney A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S.

Ann Oncol. 2018 Mar 1;29(3):758-765. doi: 10.1093/annonc/mdx774.

PMID:
29216400
15.

Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion.

Sciot R, Jacobs S, Calenbergh FV, Demaerel P, Wozniak A, Debiec-Rychter M.

Histopathology. 2018 Apr;72(5):880-883. doi: 10.1111/his.13437. Epub 2018 Jan 11. No abstract available.

PMID:
29143432
16.

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.

Mathivet T, Bouleti C, Van Woensel M, Stanchi F, Verschuere T, Phng LK, Dejaegher J, Balcer M, Matsumoto K, Georgieva PB, Belmans J, Sciot R, Stockmann C, Mazzone M, De Vleeschouwer S, Gerhardt H.

EMBO Mol Med. 2017 Dec;9(12):1629-1645. doi: 10.15252/emmm.201607445.

17.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.

Ann Oncol. 2017 Dec 1;28(12):3000-3008. doi: 10.1093/annonc/mdx527.

18.

In-depth Genetic Analysis of Sclerosing Epithelioid Fibrosarcoma Reveals Recurrent Genomic Alterations and Potential Treatment Targets.

Arbajian E, Puls F, Antonescu CR, Amary F, Sciot R, Debiec-Rychter M, Sumathi VP, Järås M, Magnusson L, Nilsson J, Hofvander J, Mertens F.

Clin Cancer Res. 2017 Dec 1;23(23):7426-7434. doi: 10.1158/1078-0432.CCR-17-1856. Epub 2017 Sep 22.

19.

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade.

Dejaegher J, Verschuere T, Vercalsteren E, Boon L, Cremer J, Sciot R, Van Gool SW, De Vleeschouwer S.

Int J Cancer. 2017 Nov 1;141(9):1891-1900. doi: 10.1002/ijc.30877. Epub 2017 Jul 19.

20.

A novel EWS-CREB3L3 gene fusion in a mesenteric sclerosing epithelioid fibrosarcoma.

Dewaele B, Libbrecht L, Levy G, Brichard B, Vanspauwen V, Sciot R, Debiec-Rychter M.

Genes Chromosomes Cancer. 2017 Sep;56(9):695-699. doi: 10.1002/gcc.22474. Epub 2017 Jul 1.

PMID:
28569045
21.

In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models.

Cornillie J, Wozniak A, Pokreisz P, Casazza A, Vreys L, Wellens J, Vanleeuw U, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P.

Mol Cancer Ther. 2017 Aug;16(8):1566-1575. doi: 10.1158/1535-7163.MCT-16-0832. Epub 2017 May 31.

22.

Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy.

Van Dievel J, Sciot R, Delcroix M, Vandeweyer RO, Debiec-Rychter M, Dewaele B, Cornillie J, Van Cann T, Meyns B, Schöffski P.

Oncol Res Treat. 2017;40(6):353-359. doi: 10.1159/000476036. Epub 2017 May 12.

23.

Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI.

De Coster L, Sciot R, Everaerts W, Gheysens O, Verscuren R, Deroose CM, Pans S, Van Laere K, Goffin KE.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1607-1608. doi: 10.1007/s00259-017-3712-6. Epub 2017 May 9. No abstract available.

PMID:
28488027
24.

Phalangeal chondrosarcoma: A rare presentation with an unusual biological behavior.

Strybol D, Hermans K, Degreef I, Sinnaeve F, Pans S, Debiec-Rychter M, Sciot R.

Hand Surg Rehabil. 2017 Jun;36(3):228-229. doi: 10.1016/j.hansur.2017.01.008. Epub 2017 Apr 7. No abstract available.

PMID:
28465204
25.

Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.

Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G, Daugaard S, Sciot R, Collin F, Messiou C, Grünwald V, Gronchi A, van der Graaf W, Wardelmann E, Judson I.

Acta Oncol. 2017 Jul;56(7):1013-1020. doi: 10.1080/0284186X.2017.1315173. Epub 2017 Apr 21.

26.

PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis.

Arts FA, Sciot R, Brichard B, Renard M, de Rocca Serra A, Dachy G, Noël LA, Velghe AI, Galant C, Debiec-Rychter M, Van Damme A, Vikkula M, Helaers R, Limaye N, Poirel HA, Demoulin JB.

Hum Mol Genet. 2017 May 15;26(10):1801-1810. doi: 10.1093/hmg/ddx081.

PMID:
28334876
27.

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schöffski P.

Eur J Cancer. 2017 Apr;75:33-40. doi: 10.1016/j.ejca.2016.12.018. Epub 2017 Feb 16.

PMID:
28214655
28.

Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma.

Requilé A, Clement PM, Bechter OE, Dumez H, Verbiest A, Sciot R, Hompes D, Sinnaeve F, Van Limbergen E, Schöffski P.

Sarcoma. 2017;2017:1781087. doi: 10.1155/2017/1781087. Epub 2017 Dec 28.

29.

Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.

Gebreyohannes YK, Schöffski P, Van Looy T, Wellens J, Vreys L, Cornillie J, Vanleeuw U, Aftab DT, Debiec-Rychter M, Sciot R, Wozniak A.

Mol Cancer Ther. 2016 Dec;15(12):2845-2852. Epub 2016 Oct 24.

30.

Cladophialophora bantiana osteomyelitis in a renal transplant patient.

Desmet S, Smets L, Lagrou K, Derdelinckx I, Neyt J, Maertens J, Sciot R, Demaerel P, Bammens B.

Med Mycol Case Rep. 2016 Jul 9;12:17-20. doi: 10.1016/j.mmcr.2016.07.002. eCollection 2016 Jun.

31.

Imaging features of chondromyxoid fibroma: report of 15 cases and literature review.

Cappelle S, Pans S, Sciot R.

Br J Radiol. 2016 Aug;89(1064):20160088. doi: 10.1259/bjr.20160088. Epub 2016 May 26.

32.

Recurrent MALAT1-GLI1 oncogenic fusion and GLI1 up-regulation define a subset of plexiform fibromyxoma.

Spans L, Fletcher CD, Antonescu CR, Rouquette A, Coindre JM, Sciot R, Debiec-Rychter M.

J Pathol. 2016 Jul;239(3):335-43. doi: 10.1002/path.4730. Epub 2016 May 20.

33.

Pulmonary metastasis of a meningioma presenting as a solitary pulmonary nodule: 2 case reports.

Leemans J, Van Calenbergh F, Sciot R, Debiec-Rychter M, Decaluwe H, Nackaerts K.

Acta Clin Belg. 2016 Apr;71(2):107-10. doi: 10.1080/17843286.2015.1133002. Epub 2016 Feb 6.

PMID:
27075807
34.

Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.

Masters SL, Lagou V, Jéru I, Baker PJ, Van Eyck L, Parry DA, Lawless D, De Nardo D, Garcia-Perez JE, Dagley LF, Holley CL, Dooley J, Moghaddas F, Pasciuto E, Jeandel PY, Sciot R, Lyras D, Webb AI, Nicholson SE, De Somer L, van Nieuwenhove E, Ruuth-Praz J, Copin B, Cochet E, Medlej-Hashim M, Megarbane A, Schroder K, Savic S, Goris A, Amselem S, Wouters C, Liston A.

Sci Transl Med. 2016 Mar 30;8(332):332ra45. doi: 10.1126/scitranslmed.aaf1471.

35.

The Filum Terminale: A Cadaver Study of Anatomy, Histology, and Elastic Properties.

De Vloo P, Monea AG, Sciot R, van Loon J, Van Calenbergh F.

World Neurosurg. 2016 Jun;90:565-573.e1. doi: 10.1016/j.wneu.2015.12.103. Epub 2016 Jan 22.

PMID:
26805693
36.

A Mass Involving the Buccal Branch of the Facial Nerve.

De Mol A, Sciot R, Politis C.

JAMA Otolaryngol Head Neck Surg. 2016 Feb;142(2):187-8. doi: 10.1001/jamaoto.2015.3077. No abstract available.

PMID:
26719906
37.

Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Prenen H, Smeets D, Mazzone M, Lambrechts D, Sagaert X, Sciot R, Debiec-Rychter M.

Oncotarget. 2015 Nov 3;6(34):36418-25. doi: 10.18632/oncotarget.5503.

38.

Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.

Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2015 Apr;8(2):112-8. doi: 10.1016/j.tranon.2015.02.004.

39.

Angiomatoid fibrous histiocytoma - case series with emphasis on a late fibrotic variant.

Wilk M, Zelger BG, Debiec-Rychter M, Sciot R, Zelger B.

J Dtsch Dermatol Ges. 2015 May;13(5):441-8. doi: 10.1111/ddg.12600.

PMID:
25918088
40.

Desmoid tumors in neurosurgery: a review of the literature.

De Vloo P, De Vlieger J, Vander Poorten V, Sciot R, van Loon J, Van Calenbergh F.

Clin Neurol Neurosurg. 2015 Feb;129:78-84. doi: 10.1016/j.clineuro.2014.12.007. Epub 2014 Dec 24. Review.

PMID:
25576767
41.

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models.

Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P.

Transl Oncol. 2014 Dec;7(6):665-71. doi: 10.1016/j.tranon.2014.09.007.

42.

Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy.

Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, Vanleeuw U, Fletcher JA, Manley PW, Debiec-Rychter M, Schöffski P.

Clin Cancer Res. 2014 Dec 1;20(23):6071-82. doi: 10.1158/1078-0432.CCR-14-1823. Epub 2014 Oct 14.

43.

Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST.

Wozniak A, Rutkowski P, Schöffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E, Limon J, Blay JY, Siedlecki JA, Wardelmann E, Sciot R, Coindre JM, Debiec-Rychter M.

Clin Cancer Res. 2014 Dec 1;20(23):6105-16. doi: 10.1158/1078-0432.CCR-14-1677. Epub 2014 Oct 7.

44.

Array CGH analysis identifies two distinct subgroups of primary angiosarcoma of bone.

Verbeke SL, de Jong D, Bertoni F, Sciot R, Antonescu CR, Szuhai K, Bovée JV.

Genes Chromosomes Cancer. 2015 Feb;54(2):72-81. doi: 10.1002/gcc.22219. Epub 2014 Sep 18.

PMID:
25231439
45.

Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child.

O'Meara E, Stack D, Phelan S, McDonagh N, Kelly L, Sciot R, Debiec-Rychter M, Morris T, Cochrane D, Sorensen P, O'Sullivan MJ.

Genes Chromosomes Cancer. 2014 Dec;53(12):991-8. doi: 10.1002/gcc.22208. Epub 2014 Aug 19.

PMID:
25139254
46.

Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.

Van Looy T, Gebreyohannes YK, Wozniak A, Cornillie J, Wellens J, Li H, Vanleeuw U, Floris G, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Sarcoma Res. 2014 Aug 10;4:10. doi: 10.1186/2045-3329-4-10. eCollection 2014.

47.

Cellular angiofibroma of the prostate: a rare tumor in an unusual location.

Wyn I, Debiec-Rychter M, Van Cleynenbreugel B, Sciot R.

Case Rep Pathol. 2014;2014:871530. doi: 10.1155/2014/871530. Epub 2014 Jul 1.

48.

Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features.

Przybyl J, Sciot R, Wozniak A, Schöffski P, Vanspauwen V, Samson I, Siedlecki JA, Rutkowski P, Debiec-Rychter M.

Int J Biochem Cell Biol. 2014 Aug;53:505-13. doi: 10.1016/j.biocel.2014.05.006. Epub 2014 May 16.

PMID:
24842110
49.

A rare central thoracic tumor.

Cuppens K, Delcroix M, Van Raemdonck D, Meyns B, Sciot R, Debiec-Rychter M, Vansteenkiste JF.

J Thorac Oncol. 2014 Jun;9(6):897-9. doi: 10.1097/JTO.0000000000000162. No abstract available.

50.

A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.

Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin LX, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FG, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M.

Nat Genet. 2014 Jun;46(6):595-600. doi: 10.1038/ng.2969. Epub 2014 May 4.

Supplemental Content

Support Center